A research team has developed a single-dose CRISPR-CasRx nanotherapy targeting the host enzyme cathepsin L (referred to as SCNC) that not only reduces SARS-CoV-2 viral load during acute infection but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results